Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia

Marquis, Miriam, Beaubois, Cyrielle, Lavallée, Vincent-Philippe, Abrahamowicz, Michal, Danieli, Coraline, Lemieux, Sébastien, Ahmad, Imran, Wei, Andrew, Ting, Stephen B., Fleming, Shaun, Schwarer, Anthony, Grimwade, David, Grey, William, Hills, Robert K., Vyas, Paresh, Russell, Nigel, Sauvageau, Guy and Hébert, Josée 2018. High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer Journal 8 (68) 10.1038/s41408-018-0103-6

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

In acute myeloid leukemia (AML), risk stratification based on cytogenetics and mutation profiling is essential but remains insufficient to select the optimal therapy. Accurate biomarkers are needed to improve prognostic assessment. We analyzed RNA sequencing and survival data of 430 AML patients and identified HMGA2 as a novel prognostic marker. We validated a quantitative PCR test to study the association of HMGA2 expression with clinical outcomes in 358 AML samples. In this training cohort, HMGA2 was highly expressed in 22.3% of AML, mostly in patients with intermediate or adverse cytogenetics. High expression levels of HMGA2 (H + ) were associated with a lower frequency of complete remission (58.8% vs 83.4%, P < 0.001), worse 3-year overall survival (OS, 13.2% vs 43.5%, P < 0.001) and relapse-free survival (RFS, 10.8% vs 44.2%, P < 0.001). A positive HMGA2 test also identified a subgroup of patients unresponsive to standard treatments. Multivariable analyses showed that H + was independently associated with significantly worse OS and RFS, including in the intermediate cytogenetic risk category. These associations were confirmed in a validation cohort of 260 patient samples from the UK NCRI AML17 trial. The HMGA2 test could be implemented in clinical trials developing novel therapeutic strategies for high-risk AML.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Additional Information: This article is licensed under a Creative Commons Attribution 4.0 International License
Publisher: Nature Publishing Group: Open Access Journals - Option B / Nature Publishing Group
ISSN: 2044-5385
Date of First Compliant Deposit: 4 September 2018
Date of Acceptance: 1 June 2018
Last Modified: 19 Oct 2019 02:48
URI: http://orca.cf.ac.uk/id/eprint/114584

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics